NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, reported Friday that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases.
Read the full article: NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger //
Source: https://www.businesswire.com/news/home/20200110005495/en/NeuroBo-Pharmaceuticals-Gemphire-Therapeutics-Complete-Merger